Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VG-3927 · 1 trial · 2 indications
To evaluate the safety and tolerability of VG-3927
| Arm | Type | Description |
|---|---|---|
| Single and Multiple Ascending Dose | EXPERIMENTAL | Ascending single doses and multiple doses for healthy volunteers. |
| Placebo | PLACEBO_COMPARATOR | Matching placebo |
| Alzheimer's Disease | EXPERIMENTAL | Single Dose Open-label |
| Name | Type | Description |
|---|---|---|
| VG-3927 | DRUG | Dose Escalation |
| Placebo | DRUG | Dose Escalation |
Inclusion Criteria: * The participant is deemed healthy by the principal investigator, as determined by prestudy medical evaluation * The participant voluntarily agrees to participate in this study and signs an institutional review board approved informed consent Exclusion Criteria: * The partici...
VG-3927 is an investigational small molecule being studied for use in healthy adults and patients with Alzheimer's disease. It is in Phase 1 clinical development for neurology indications. The drug is not approved and remains under investigation for its potential effects in these populations.
VG-3927 is being developed by Vigil Neuroscience, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VIGL. The company is conducting clinical research on this investigational small molecule for neurological conditions.
VG-3927 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study has been completed, evaluating the drug in healthy adults and patients with Alzheimer's disease.
VG-3927 has one completed Phase 1 clinical trial, identified as NCT06343636. This study, titled 'A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease,' enrolled 115 participants in the United States and Australia. The trial was randomized, double-blind, and placebo-controlled.
No alternative names for VG-3927 have been reported. The drug is identified by its code name VG-3927 in clinical trial records and is being developed by Vigil Neuroscience, Inc. under this designation.